ArticleChild's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery2025
Craniopharyngioma in children. An age-based analysis on our 11 year experience with the endoscopic endonasal approach.
Article in Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this work is to perform an age-based analysis to define the criteria for the best management from a clinical and surgical point of view of craniopharyngiomas in children on patients treated with an endoscopic endonasal approach.
methodsFor this retrospective study, the databank of Meyer Children's Hospital IRCCS was used. 29 consecutive patients treated with an endonasal endoscopic technique between January 2013 and January 2024 were enrolled in the study. All patients underwent endocrinological, ophthalmological and radiological examination upon admission. Standard follow-up appointments at the outpatient clinic were given to the patients at 1, 3 months and 6 months postoperatively and successively annual appointments were made.
resultsThe mean follow-up was 5.6 5.6 years ± 4.1 years. 40% of the patients presented with hydrocephalus, 41% of the children had an endocrine dysfunction as the primary symptom and visual impairment was present in 55% of the cases. Patients were subdivided into 3 groups according to age sub-stratification. Group A included young patients with ages between 3-6 years old (9 patients), Group B consisted of children in the pre-puberal age (7-12 years old - 12 patients) and Group C was formed by teenagers (13-18 years old - 8 patients). Group A presented more aggressive and voluminous tumors, with a higher recurrence and a higher risk of obesity. The period from first symptoms to diagnosis was significantly higher in Group C compared to Group B: 23.4 months versus 7.7 months respectively. Visual impairment was more frequent in Group A compared to Group C (p = 0.02).
conclusionsThe age-based analysis showed some interesting findings. Younger children with an age inferior to 6 years old tend to present with more voluminous tumors and visual impairment as the first symptom, Once visual symptoms are manifested, they tend to be unchanged and do not show improvement, even after surgery. In teenagers the diagnosis can be delayed due to the misrecognition of the symptoms. However, our results showed that EEA is useful and feasible in all age groups, achieving a gross total/subtotal resection even in cases of recurrence. If used as the first treatment of choice the chances of gross total resection without further recurrence are higher.
Indexed as
Identifiers
41269337What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.